Best Biometrics Vendors for Phase III Trials (2026)

Who this guide is for

This guide is for clinical development leaders, programme directors and biotech teams preparing a pivotal Phase III trial who need a biometrics partner for design, analysis or submission datasets. It is also for sponsors whose Phase II statistician cannot scale to a multiregional confirmatory study, and for teams whose full-service CRO contract leaves biometrics to be bought separately.

Phase III is where statistical decisions carry the most weight: they determine sample size, cost and whether the result can support a marketing application. If you are looking for the best biometrics vendors for Phase III trials, use the vendor cards and table on this page as a starting point, not a verdict. They show which biometrics vendors are listed and what their profiles state; confirm pivotal-trial experience directly before you shortlist.

What a Phase III biometrics vendor does — and when you need one

In a confirmatory trial, the biometrics team owns the statistical backbone of the study. Before first patient in, it agrees the primary endpoint and estimand, the multiplicity strategy for secondary endpoints, the sample size and the randomisation scheme. During the trial it supports blinded data review, prepares analyses for any data monitoring committee and keeps the statistical analysis plan aligned with protocol amendments. After database lock it produces the analysis datasets, the tables, listings and figures for the clinical study report, and the standardised datasets and metadata for submission.

Many sponsors split this work: an independent statistician for the data monitoring committee, a specialist design consultancy for simulation of complex designs, and a programming team with capacity for the volume of outputs a pivotal study produces. Others buy biometrics bundled with data management from one provider.

Typical trigger points are the end-of-Phase II decision, preparation for scientific advice, a design with interim analyses or adaptive elements, a multiregional programme, or the realisation that in-house programming capacity cannot meet the post-lock timeline.

How to evaluate a Phase III biometrics vendor

Confirmatory trial design experience

Ask which pivotal designs the team has worked on and in which indications. Multiplicity control, non-inferiority margins, time-to-event endpoints and group sequential boundaries all require experience that early-phase work may not provide. Ask how the vendor would defend its proposed design in a regulatory meeting, and what simulation it would run to support it.

Estimands, missing data and sensitivity analyses

The ICH E9(R1) addendum expects a clear definition of the treatment effect being estimated and how intercurrent events, such as discontinuation or rescue medication, are handled. In Phase III these choices drive the primary analysis. Ask for a redacted statistical analysis plan and judge how clearly it sets out the primary estimand, the handling of missing data and the sensitivity analyses that support it.

Interim analyses, data monitoring committees and adaptive elements

Many Phase III trials include interim looks for efficacy, futility or sample size re-estimation. Ask how the vendor structures the independent statistical team, how it keeps unblinded results away from the study team, and how it documents the charter and the decision rules. If your design is adaptive, ask how its approach aligns with the ICH E20 guideline on adaptive designs and the FDA guidance on adaptive designs.

Multiregional consistency

Under ICH E17, multiregional trials should be planned so that regional results can be interpreted. Ask how the vendor would approach regional allocation, pre-specified subgroup analyses and the presentation of consistency for the regulators you plan to approach.

Programming capacity at database lock

Pivotal studies produce large output packages under tight timelines. Ask how many programmers would be assigned at lock, how validation is planned, whether programs are developed and tested on blinded or dummy data in advance, and whether the vendor runs dry runs before lock.

Submission datasets and integrated analyses

Ask for examples of SDTM, ADaM, Define-XML and reviewer guide packages the vendor has delivered, and whether it has supported integrated summaries of safety and efficacy that pool several studies. Conversion at the end of a programme is a common cause of delay.

Governance across the CRO, data management and biometrics

In many Phase III programmes the CRO runs operations, one vendor manages the data and another analyses it. Each hand-off is a place where timelines slip and issues go unowned. Ask how the biometrics vendor takes part in data review meetings, how it raises data issues that affect the analysis, how it agrees data transfer specifications, and who chairs the decision when the statistical analysis plan and the data disagree. A short governance plan, with named owners and escalation routes, is worth asking for at proposal stage.

Blinded data review before lock

Reviewing blinded, pooled data before lock lets the team spot outliers, protocol deviations and unexpected distributions while there is still time to act. Ask how the vendor runs blinded data review, how decisions about analysis populations are documented before unblinding, and how those decisions feed into the final statistical analysis plan.

Responsiveness to regulator questions

After submission, regulators ask for additional analyses, often with short deadlines. Ask whether the vendor keeps the team available after the clinical study report, and how quickly it can turn around ad hoc analyses.

Phase III biometrics vendors at a glance

The table below lists biometrics vendors whose profiles include Phase III among their study phases, so you can compare service model, footprint and therapeutic coverage before opening individual pages.

The fields come from each vendor's Clinical Vendor Compare profile. Listing Phase III means the vendor's record includes that phase; it does not show how many pivotal trials a team has supported or in which indications. Several records describe a generalist remit and a broad service description, and two of the vendors below are real-world evidence platforms rather than trial biometrics teams. Treat the table as a map of who to ask, then verify pivotal experience in conversation.

Phase III biometrics vendor profiles

CTI (Biometrics)

CTI's biometrics record lists Phase I to Phase III coverage of small and medium-scale studies in oncology, rare diseases, CNS and cardiovascular medicine, from a United States headquarters with a global footprint. It is positioned for sponsors who want biostatistics consulting alongside data management. Phase III fit: relevant if you want design advice and data management from one team. Its record notes a mid-size organisation with limited global reach, so test resourcing for a large multiregional study.

Lambda (Biometrics)

Lambda's record describes an India-headquartered CRO offering biostatistics, data management and trial services, covering Phase I to Phase IV in oncology, infectious disease, diabetes and cardiovascular medicine, with CDISC standards listed among its strengths. Phase III fit: worth considering for programming and standards capacity. Ask about the size of the team available at database lock, overlap with your working hours, and the senior review of key outputs.

Aetion

Aetion is listed as a software platform for real-world evidence focused on causal inference, regulatory real-world evidence submissions, health technology assessment evidence and emulation of randomised trials. Its record notes that it does not collect data and relies on external data partnerships. Phase III fit: relevant to evidence around a pivotal trial, such as context for rare outcomes or payer evidence, not to the design and analysis of the randomised study itself.

Algorics Biostatistics

Algorics' record lists a biometrics and data science provider with a global footprint and a generalist remit across Phase I to Phase IV. It is positioned for sponsors needing outsourced data science, statistics or programming capacity. Phase III fit: a candidate where the gap is capacity rather than design leadership. Ask how it adapts to your standards and governance, which its record flags as an area to manage.

Berry Consultants

Berry Consultants' record describes a focus on adaptive trial design, Bayesian analysis and simulation, with a global footprint. Phase III fit: relevant when the confirmatory design itself is complex, for example with response-adaptive features, several interim decisions or a platform structure. Ask how it hands designs over to the team that will run the trial, and how it supports the simulation report and regulatory discussion.

BioStata

BioStata is listed as a biometrics and data science provider with a global footprint and a generalist remit, covering Phase I to Phase IV. Its stated best fit is programmes needing statistics, programming, data management or analytics. Phase III fit: the record does not describe pivotal experience in detail, so ask for examples of confirmatory studies it has analysed and the size of the team it would assign at lock.

Certara Biometrics

Certara Biometrics' record lists a global biometrics provider covering Phase I to Phase IV with a focus on statistics, programming, data management and analytics. Phase III fit: relevant for sponsors who want biometrics from a provider whose wider business includes modelling and simulation. Ask how quantitative pharmacology work, if you need it, would connect with the statistical analysis of your pivotal study.

Clinical ink Data & Analytics

This record lists a biometrics and data science provider with a global footprint covering Phase I to Phase IV, focused on statistics, programming, data management and analytics. Phase III fit: relevant if your trial collects substantial electronic source or patient-reported data and you want analytics close to the data. Ask for confirmatory analyses the team has delivered and how it validates programs.

CluePoints

CluePoints' record describes a focus on risk-based quality management, anomaly detection using statistical and machine-learning methods, and risk documentation, with a European and global footprint. Phase III fit: relevant to central statistical monitoring during a large trial, which ICH E6(R3) encourages as part of risk-proportionate oversight, rather than to the primary efficacy analysis.

COTA

COTA's record lists a North American real-world evidence company in oncology and haematology that classifies patients into clinically relevant subgroups using its own grading approach. Its record notes an oncology-only, United States focus. Phase III fit: relevant to oncology sponsors who need real-world context, for example to inform assumptions or payer evidence, alongside rather than instead of a trial biometrics team.

Engagement and pricing models for Phase III

Phase III biometrics is commonly bought as a unit-based contract covering defined deliverables, an FTE or functional service arrangement giving named statisticians and programmers for the programme, or as part of a full-service CRO contract. Some sponsors combine models: a design specialist for simulation and the data monitoring committee, and a capacity provider for programming.

The main cost drivers are the size of the output package, the number of interim analyses and committee meetings, simulation for complex designs, submission datasets and integrated analyses, and the volume of ad hoc analyses requested after submission. Agree in advance how protocol amendments and regulator questions will be priced, and keep the independent statistical team's scope separate in the contract.

Questions to put in your Phase III biometrics RFP

• Which confirmatory trials has the proposed lead statistician designed or analysed, and in which indications?
• How would you define the primary estimand and handle intercurrent events for our endpoint?
• What multiplicity strategy do you propose for our secondary endpoints, and why?
• How is the independent statistical team for interim analyses separated from the study team?
• What simulation would you run to support the design, and how would it be documented for regulators?
• How many programmers will be assigned at database lock, and what is your dry-run plan?
• Which outputs are double programmed?
• Can you show examples of SDTM, ADaM, Define-XML and reviewer guide packages delivered for submission?
• How would you address regional consistency under ICH E17 for the regions we plan to file in?
• How quickly can you turn around ad hoc analyses requested by regulators after submission?
• What triggers a change order, and how are protocol amendments priced?

Due-diligence red flags

• A proposed lead statistician with only early-phase experience for a pivotal study.
• No written approach to estimands, multiplicity or missing data in the proposal.
• No independent team or documented firewall for interim analyses.
• Programming capacity at lock described in general terms with no named team.
• Standardised datasets treated as an end-of-study conversion task.
• Real-world evidence or machine-learning outputs offered as a substitute for the randomised analysis.
• Quotes that are silent on regulator questions after submission.
• Reluctance to share a timeline from database lock to topline results.

Shortlist Phase III biometrics vendors on Clinical Vendor Compare

Start in the vendor directory and filter for biometrics and data science, then open profiles to check which list Phase III. Place a few side by side on the compare page to separate design specialists, programming capacity providers and real-world evidence platforms. For the wider operational picture, read the guide to Phase III CROs, and for an overview of the category see the guide to biometrics vendors for clinical trials. When your scope is clear, use the sponsor RFP tool to brief vendors. If you have worked with any of these vendors, please write a review so the next sponsor has evidence to work from.